Dong-A announces positive results for Zydena in hypertensive and diabetic patients

Published: 2007-11-29 06:57:00

Updated: 2007-11-29 06:57:00

Dong-A Pharmaceutical says it has successfully completed its 10-month clinical study for 135 hypertensive patients and 156 diabetic patients in 13 local university hospitals, including Seoul National University Hospital and Korea University Anam Hospital, for Zydena (udenafil), its new long actin...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK